Navigation Links
PolyU develops a new class of antibiotic candidates for fighting against superbugs
Date:9/24/2019

Drug resistance has been declared as one of the biggest threats to global health in 2019 by the World Health Organization, with MRSA becoming one of the most serious concerns. Hong Kong cannot be spared from the worsening scourge of MRSA. In 2018, there were 1,218 reported cases of community-associated MRSA (CA-MRSA), or a seven-fold of the figure in 2007 – the year the disease became notifiable in Hong Kong. As of August this year, there were already 839 cases reported. Despite of tremendous pharmaceutical research and development investments worldwide, the search for new antibiotics has showed no progress since mid-1980s.

The development of “Nusbiarylins”, a new class of antimicrobial agents, by the research team of the State Key Laboratory of Chemical Biology and Drug Discovery of PolyU’s Department of Applied Biology and Chemical Technology (ABCT), is thus a breakthrough in the battle against multi-drug resistant bacterial infections. The interdisciplinary team, led by Dr MA Cong, Assistant Professor in ABCT, comprises of experts from both PolyU and Faculty of Medicine of The Chinese University of Hong Kong.

“Our research is now in the stage of animal studies, conducting infectious model studies and pharmacokinetic studies. These are the critical steps preceding clinical trials on human for drug development. At this moment, there are very few antibiotic related studies being able to complete such stage worldwide. Our findings so far are very promising. We believe further studies on these compounds will contribute to a new era of antibiotic discovery, contributing towards the fight against superbugs,” said Dr Ma.

New target being identified by innovative antimicrobial mechanism

Most antibiotics currently in the market fight against bacteria through disrupting its DNA synthesis or protein functions. The innovative antimicrobial mechanism developed by PolyU team focuses on inhibiting the interaction between two proteins, NusB and NusE, which is crucial for synthesis of bacterial ribosomal RNA (rRNA). By designing small molecules to disrupt NusB-NusE interaction, bacterial cell proliferation can thus be curbed.

The team developed a model basing on the structure of NusB and NusE, and applied computer-aided screening to screen about 5,000 small molecule compounds with drug-like properties to explore for inhibitors for NusB-NusE interaction. The shortlisted compounds were then put to tests for antimicrobial activity against different MRSA strains. A compound, (E)-2-{[(3-ethynylphenyl)imino]methyl}-4-nitrophenol (hereafter addressed as MC4), was identified as having much effective antibacterial abilities than the commonly used antibiotics. The Minimum Inhibitory Concentration (note: MIC denotes the lowest concentration of a chemical/drug for preventing bacterial growth) of MC4 for some MRSA strains are as low as 8 µg/mL, compared to the MICs of >64 µg/mL demonstrated by two antibiotics in the market, oxacillin and gentamicin.

Test of MC4 on human lung and skin cells (infections caused by MRSA often occur in these tissues) indicated no significant toxicity. The fact that NusB and NusE exist only in bacteria and not human cells has also addressed toxicity concern.

“Nusbiarylins” — a new class of antibiotic candidates
The research team has further structurally modified MC4 for optimization, and 167 analogues were synthesized so far. The new class of compounds are named as “Nusbiarylins” (basing on their target protein “NusB” and their “biaryl” structure). Laboratory test of Nusbiarylins against a panel of MRSA strains proved their consistent antibacterial activity, some with MIC as low as 0.125 µg/mL, much better than commonly used antibiotics, including vancomycin with the MIC of 1 µg/mL which is labelled as the “last resort” antibiotic drug in the United States.

Further pre-clinical studies on the in vitro pharmacological properties of Nusbiarylins on human cells indicated that the compounds:
—    leading to nearly no hemolysis (i.e. human blood cell breaking), an indication of being safe for injection; and
—    with excellent result in intestine absorption, implying being effective for oral taking.

The findings have been recently published in leading scientific journals (listed below). The innovation has also won the “Global Innovation Award” at the TechConnect World Innovation Conference and Expo 2019 held in June in the United States.

Recently published journal papers:-

Xiao Yang, Ming Jing Luo, Apple C M Yeung, Peter J Lewis, Paul Kay-sheung Chan, Margaret Ip, Cong Ma. First-In-Class Inhibitor of Ribosomal RNA Synthesis with Antimicrobial Activity against Staphylococcus aureus. Biochemistry 2017, 56, 5049-5052.

Tsz Fung Tsang, Yangyi Qiu, Lin Lin, Jiqing Ye, Cong Ma, Xiao Yang. Simple Method for Studying in Vitro Protein–Protein Interactions Based on Protein Complementation and Its Application in Drug Screening Targeting Bacterial Transcription. ACS Infectious Diseases 2019, 5, 521-527.

Yangyi Qiu, Shu Ting Chan, Lin Lin, Tsun Lam Shek, Tsz Fung Tsang, Nilakshi Barua, Yufeng Zhang, Margaret Ip, Paul Kay-sheung Chan, Nicolas Blanchard, Gilles Hanquet, Zhong Zuo, Xiao Yang, Cong Ma. Design, Synthesis and Biological Evaluation of Antimicrobial Diarylimine and Amine Compounds Targeting the Interaction between the Bacterial NusB and NusE Proteins. European Journal of Medicinal Chemistry 2019, 178, 214-231.

Yangyi Qiu, Shu Ting Chan, Lin Lin, Tsun Lam Shek, Tsz Fung Tsang, Yufeng Zhang, Margaret Ip, Paul Kay-sheung Chan, Nicolas Blanchard, Gilles Hanquet, Zhong Zuo, Xiao Yang, Cong Ma. Nusbiarylins, a New Class of Antimicrobial Agents: Rational Design of Bacterial Transcription Inhibitors Targeting the Interaction between the NusB and NusE Proteins. Bio-organic Chemistry 2019, 92, 103203.

Read the full story at https://www.prweb.com/releases/polyu_develops_a_new_class_of_antibiotic_candidates_for_fighting_against_superbugs/prweb16597213.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles
2. PolyU Strikes a Deal with Kinex Pharmaceuticals
3. EMEA Polyurethane Chemicals & Products Market Analysed & Forecast in In-demand IAL Consultants Report Available at MarketPublishers.com
4. Global Overview of the Spray Polyurethane Foam (SPF) & One Component Foam (OCF) : Industry Analysis, Size, Share, Trends And Forecast Research Report by Researchmoz
5. Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com
6. Advanced Solutions Develops New Automation Technology
7. FireflySci Develops New Agilent Flow Cell Line for HPLC Machines
8. Ariste Medical Develops Drug-Eluting Mesh For More Effective Open Hernia Repair
9. Control Micro Systems Develops Countermeasures to Battle Counterfeit Drugs
10. Pharma Leader TGV-Laboratories Develops Breakthrough Drug to Fight ‘Antibiotic Apocalypse’
11. From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2020)... ... February 12, 2020 , ... Arriello , ... is adopting Veeva Vault Safety™ as part of the company’s continued ... of data, processing of safety information such as SUSARs and ICSRS, aggregate report ...
(Date:2/11/2020)... , ... February 11, 2020 , ... ... residuals solutions services in North America, today announced that the City of Fort ... to its biosolids management needs. Commencing in April of 2020, Synagro will assume ...
(Date:2/5/2020)... FARMINGTON, Conn. (PRWEB) , ... February 04, 2020 ... ... that develops tools for characterizing microbiome populations down to the strain level, has ... Limited, will sell Shoreline Biome’s microbiome kits and other products to companies and ...
(Date:2/3/2020)... ... February 03, 2020 , ... Ovation Travel ... Firm Travel, Technology Industry Travel and Biotech/Healthcare Industry Travel Indexes. , All of ... the following statistics:, Average airfare price paid Domestically, ...
Breaking Biology Technology:
(Date:1/27/2020)... ... , ... On Thursday, February 20, 2020 at 10am EST (3pm GMT/UK), join ... Richard Castle, Global Account Manager Medical Device at PRISYM ID for an ... timing deadlines, best practices in creating and submitting product data and best practices in ...
(Date:1/24/2020)... ... 24, 2020 , ... Worldwide Business with kathy ireland® has announced ... Vice President of Sales and Marketing Jeff Maier to discuss their innovative technology, High-Speed ... Sunday, Jan. 26, 2020 at 5:30 p.m. EST and internationally on Bloomberg Television on ...
(Date:1/22/2020)... Calif. (PRWEB) , ... January 21, 2020 , ... ... Robert Pozil to lead the company’s new Business Development Department. The move, which ... Mr. Pozil had been previously serving as the company’s Senior Vice President where ...
Breaking Biology News(10 mins):